BeOne Medicines (BEIGF) Receivables (2017 - 2026)

BeOne Medicines (BEIGF) has reported Receivables for 10 consecutive years, with $1.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables rose 37.03% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 37.03% increase from a year earlier, with the FY2025 full-year figure at $865.1 million, up 27.92% from the prior year.
• Receivables was $1.1 billion for Q2 2026 at BeOne Medicines, up from $938.0 million in the prior quarter.
• Over five years, Receivables peaked at $1.1 billion in Q2 2026 and troughed at $174.9 million in Q2 2022.
• A 5-year average of $524.5 million and a median of $482.4 million in 2024 frame the typical range for Receivables.
• The widest YoY moves for Receivables: up 117.18% in 2022, down 63.9% in 2022.
• Over 5 years, Receivables stood at $176.2 million in 2022, then jumped by 104.17% to $359.8 million in 2023, then soared by 87.98% to $676.3 million in 2024, then advanced by 27.92% to $865.1 million in 2025, then climbed by 22.09% to $1.1 billion in 2026.
• The last three Receivables figures came in at $1.1 billion (Q2 2026), $938.0 million (Q1 2026), and $865.1 million (Q4 2025), per Business Quant data.